ERBB2 and gastric cancer: Hereby, we first performed a multicenter, phase I study to prospectively assess the safety and pharmacokinetic (PK) characteristics of pyrotinib alone or plus docetaxel in refractory HER2‐positive GC patients, and explore the preliminary antitumor activity as well.